FirstMark PREvent is the first multiple biomarker test that accurately predicts near term (within 2-3 years) risk of myocardial infarction for suspected or confirmed coronary artery disease (CAD) patients. It is a critical advancement in cardiovascular medicine addressing the unmet need to assess risk of near term MI. PREvent provides physician’s diagnostic clarity in identifying CAD patients that are in most urgent need of aggressive treatment and monitoring.

 
  • FirstMark Trust

    We value your privacy and data security but most of all we value your trust.


    Privacy Policy >

  •  
     
  • Keep in Touch

    Find out via email about new Firstmark developments.


  •